Leptin-Induced HLA-G Inhibits Myometrial Contraction and Differentiation.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
10 03 2022
Historique:
received: 31 01 2022
revised: 04 03 2022
accepted: 07 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 14 4 2022
Statut: epublish

Résumé

Maternal obesity is associated with a wide spectrum of labour disorders, including preterm birth. Leptin, a pro-inflammatory adipokine and a key factor of obesity, is suspected to play a major role in these disorders. OB-R, its receptor, is expressed on macrophages and myocytes, two cell types critical for labour onset. Macrophages secrete reactive oxygen species/pro-inflammatory cytokines, responsible for myometrial differentiation while myocytes control uterine contractions. In this study, we assessed the effect of leptin on myometrial contraction and differentiation using our validated co-culture model of human primary macrophages and myocytes. We demonstrated that leptin had a different effect on myocytes and macrophages depending on the dose. A low leptin concentration induced a tocolytic effect by preventing myocytes' contraction, differentiation, and macrophage-induced ROS production. Additionally, leptin led to an increase in HLA-G expression, suggesting that the tocolytic effect of leptin may be driven by HLA-G, a tolerogenic molecule. Finally, we observed that recombinant HLA-G also prevented LPS-induced ROS production by macrophages. Altogether, these data provide a putative molecular mechanism by which leptin may induce immune tolerance and therefore interfere with labour-associated mechanisms. Therefore, HLA-G represents a potential innovative therapeutic target in the pharmacological management of preterm labour.

Identifiants

pubmed: 35326405
pii: cells11060954
doi: 10.3390/cells11060954
pmc: PMC8946078
pii:
doi:

Substances chimiques

HLA-G Antigens 0
Leptin 0
Reactive Oxygen Species 0
Tocolytic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Conseil Régional de Bourgogne
ID : OBEDI

Références

Am J Reprod Immunol. 2007 Apr;57(4):277-86
pubmed: 17362389
Gene. 2016 Oct 10;591(1):209-213
pubmed: 27393653
Acta Obstet Gynecol Scand. 2021 Mar;100(3):521-530
pubmed: 33031566
Hum Reprod. 2015 Oct;30(10):2263-74
pubmed: 26307092
Free Radic Biol Med. 2000 Sep 1;29(5):388-96
pubmed: 11020659
J Immunol. 2021 Nov 12;:
pubmed: 34772698
Obesity (Silver Spring). 2011 Feb;19(2):416-21
pubmed: 20725059
Physiol Behav. 2006 Jun 30;88(3):249-56
pubmed: 16782141
Mol Hum Reprod. 2015 Aug;21(8):672-86
pubmed: 26002969
Biol Reprod. 2013 Feb 21;88(2):45
pubmed: 23303680
Am J Obstet Gynecol. 2014 May;210(5):428.e1-9
pubmed: 24321446
Hum Reprod. 1999 Jan;14(1):229-36
pubmed: 10374126
J Vis Exp. 2014 Sep 09;(91):e51554
pubmed: 25226391
Int J Mol Sci. 2020 Aug 16;21(16):
pubmed: 32824322
Genome Biol. 2005;6(2):R12
pubmed: 15693941
JAMA. 2013 Jun 12;309(22):2362-70
pubmed: 23757084
Med Hypotheses. 2010 Jan;74(1):81-2
pubmed: 19692183
Mol Hum Reprod. 2016 Feb;22(2):143-57
pubmed: 26690900
J Reprod Immunol. 2017 Feb;119:31-37
pubmed: 27984763
JAMA. 2016 Jun 7;315(21):2284-91
pubmed: 27272580
Biol Reprod. 2014 Jul;91(1):10
pubmed: 24829032
Int J Obes (Lond). 2008 Dec;32 Suppl 7:S120-6
pubmed: 19136980
Exp Cell Res. 1987 Feb;168(2):422-30
pubmed: 2433137
Front Immunol. 2020 Oct 22;11:592010
pubmed: 33193435
Am J Obstet Gynecol. 2011 Oct;205(4):363.e1-9
pubmed: 21784405
Am J Pathol. 2011 Aug;179(2):838-49
pubmed: 21801872
Carcinogenesis. 2007 Feb;28(2):455-64
pubmed: 16891627
FASEB J. 2015 Jun;29(6):2653-66
pubmed: 25757563
Placenta. 2015 Apr;36(4):419-26
pubmed: 25649687
Am J Obstet Gynecol. 2006 Aug;195(2):504-9
pubmed: 16647683
J Am Heart Assoc. 2021 Sep 7;10(17):e020717
pubmed: 34431359
Ann Med Surg (Lond). 2021 Nov 14;72:103050
pubmed: 34815864
Clin Cancer Res. 2013 Oct 15;19(20):5564-71
pubmed: 23897901
Am J Perinatol. 2018 Jan;35(1):59-64
pubmed: 28800658
BJOG. 2011 Apr;118(5):578-88
pubmed: 21265999
Endocrinology. 1997 Oct;138(10):4501-4
pubmed: 9322972
BJOG. 2010 Feb;117(3):314-20
pubmed: 20015306
Br J Pharmacol. 2015 Jun;172(12):2974-90
pubmed: 25653112
Am J Obstet Gynecol. 2012 May;206(5):447.e7-16
pubmed: 22542123
Annu Rev Physiol. 2000;62:413-37
pubmed: 10845097
Cells. 2021 Dec 31;11(1):
pubmed: 35011690
Placenta. 2009 Mar;30 Suppl A:S90-5
pubmed: 19010537
Sci Rep. 2021 Oct 6;11(1):19863
pubmed: 34615905
N Engl J Med. 1996 Feb 1;334(5):292-5
pubmed: 8532024
Reproduction. 2005 Nov;130(5):569-81
pubmed: 16264088
Proc Nutr Soc. 2005 Feb;64(1):31-8
pubmed: 15877920
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1025-1036
pubmed: 27743975
Biol Reprod. 2020 May 26;102(6):1326-1339
pubmed: 32167534
Endocr J. 2004 Apr;51(2):177-87
pubmed: 15118268

Auteurs

Maeva Wendremaire (M)

UMR 1231, Lipides Nutrition Cancer, INSERM, F-21000 Dijon, France.
UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France.

Tatiana E Lopez (TE)

UMR 1231, Lipides Nutrition Cancer, INSERM, F-21000 Dijon, France.
UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France.

Marina Barrichon (M)

UMR 1231, Lipides Nutrition Cancer, INSERM, F-21000 Dijon, France.
UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France.

Hang Zhang (H)

UMR 1231, Lipides Nutrition Cancer, INSERM, F-21000 Dijon, France.
UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France.
School of Basic Medical Science, Hangzhou Normal University, Hangzhou 311121, China.

Tarik Hadi (T)

UMR 1231, Lipides Nutrition Cancer, INSERM, F-21000 Dijon, France.
UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France.

Xiang-Yang Ye (XY)

School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.

Fabrice Neiers (F)

UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France.
Centre des Sciences du Goût et de l'Alimentation, INRAE, CNRS, Université Bourgogne Franche-Comté, F-21000 Dijon, France.

Marc Bardou (M)

UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France.
CIC 1432, INSERM, Université de Bourgogne Franche-Comté, F-21000 Dijon, France.

Paul Sagot (P)

Service de Gynécologie-Obstétrique, Centre Hospitalo-Universitaire Dijon, F-21000 Dijon, France.

Carmen Garrido (C)

UMR 1231, Lipides Nutrition Cancer, INSERM, F-21000 Dijon, France.
UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France.
Department of Medical Oncology, Centre Georges François Leclerc, F-21000 Dijon, France.

Frédéric Lirussi (F)

UMR 1231, Lipides Nutrition Cancer, INSERM, F-21000 Dijon, France.
UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France.
Plateforme PACE, Laboratoire de Pharmacologie-Toxicologie, Centre Hospitalo-Universitaire Besançon, F-25000 Besançon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH